| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Asunercept | CAN-008; APG-101 | Phase 2 Clinical | Apogenix Gmbh | Glioblastoma; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19) | Details |
| M3T01 | M3T01 | Phase 1 Clinical | Providence Health & Services | Solid tumours | Details |